Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
China
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong Russia
Hematologist of the Regional Hematology Center in Clinical Hospital No. 2 of the Ministry of Health, Vladivostok